UofL researchers receive $3.6 million to study the role of arsenic exposure in causing health problems

University of Louisville researchers have received $3.6 million in new grant funding to study the role of arsenic exposure in causing cancer and other major health concerns.

Recaticimab injection every 1-3 months may safely lower bad cholesterol

A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking

November 13, 2023

New gene therapy offers hope for beta thalassemia patients

UCSF Benioff Children’s Hospital Oakland provides new therapy to first patient since FDA approval.

September 1, 2023

BMS strengthens NSCLC market share with ROS1 drug Augtyro – Pharmaceutical Technology

Share this article The Phase I/II TRIDENT-1, which is evaluating Augtyro (repotrectinib) is expected to be completed by February 2028. Credit: nitpicker/Shutterstock.com The US Food

November 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.